Effects of Semaglutide in HIV-Associated Lipohypertrophy
Status:
Recruiting
Trial end date:
2024-03-31
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blinded, placebo-controlled trial designed to assess the effect
of the GLP-1 receptor agonist, semaglutide, on visceral and ectopic fat, insulin resistance,
inflammation markers, and the downstream effect of cardiovascular risk in people with HIV.
The primary endpoints will be visceral and ectopic fat changes over the study period. The
secondary endpoints will include changes in markers of inflammation, immune activation, gut
integrity, and cardiovascular disease risk assessment.
Phase:
Phase 2
Details
Lead Sponsor:
Case Western Reserve University
Collaborators:
Medical University of South Carolina National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)